Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned an average recommendation of “Buy” from the twenty-three analysts that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $405.20.
A number of equities research analysts have commented on the stock. Raymond James increased their price objective on shares of DexCom from $395.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Oppenheimer initiated coverage on shares of DexCom in a research report on Tuesday, July 28th. They issued a “buy” rating and a $445.00 target price on the stock. JPMorgan Chase & Co. increased their target price on shares of DexCom from $360.00 to $450.00 and gave the company an “overweight” rating in a research report on Monday, July 27th. Morgan Stanley increased their target price on shares of DexCom from $377.00 to $428.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 29th. Finally, Stifel Nicolaus increased their target price on shares of DexCom from $385.00 to $500.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th.
In related news, CFO Quentin S. Blackford sold 12,886 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $398.30, for a total value of $5,132,493.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Steven Robert Pacelli sold 1,531 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $409.37, for a total transaction of $626,745.47. Following the completion of the sale, the executive vice president now owns 51,482 shares of the company’s stock, valued at approximately $21,075,186.34. The disclosure for this sale can be found here. Insiders sold a total of 46,939 shares of company stock valued at $19,178,750 in the last 90 days. Company insiders own 0.69% of the company’s stock.
Shares of DXCM opened at $397.97 on Wednesday. DexCom has a fifty-two week low of $144.78 and a fifty-two week high of $456.23. The firm’s 50 day moving average price is $421.38 and its 200 day moving average price is $364.11. The company has a quick ratio of 7.17, a current ratio of 7.58 and a debt-to-equity ratio of 1.23. The company has a market cap of $38.10 billion, a P/E ratio of 181.72, a PEG ratio of 3.80 and a beta of 0.81.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, July 28th. The medical device company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.48. DexCom had a net margin of 11.93% and a return on equity of 29.01%. The company had revenue of $451.80 million for the quarter, compared to the consensus estimate of $415.21 million. During the same period in the prior year, the firm posted $0.08 EPS. The company’s quarterly revenue was up 34.3% compared to the same quarter last year. Research analysts forecast that DexCom will post 2.67 earnings per share for the current year.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: How do CD ladders protect against rising interest rates?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.